Literature DB >> 21986195

Role of OGG1 Ser326Cys polymorphism and 8-oxoguanine DNA damage in risk assessment of squamous cell carcinoma of head and neck in North Indian population.

Anil Kumar1, Mohan Chand Pant, Hirdya Shanker Singh, Shashi Khandelwal.   

Abstract

Squamous cell carcinoma of head and neck (SCCHN), one of the leading cancers worldwide, is most prevalent in Indian sub-continent. The major risk factors involved are smoking and consumption of alcohol, since they provide high free radical generating environment. We studied 8-oxoguanine DNA-glycosylase (OGG1) Ser326Cys polymorphism in 278 SCCHN cases and 278 matched controls by PCR-RFLP and observed that the variant genotype Ser/Cys exhibited an enhanced risk of ∼1.7 folds (OR=1.71, 95% CI=1.20-2.93) and Cys/Cys ∼2.5 folds (OR=2.55, 95% CI=1.29-5.00). Furthermore, we found a significant increase in salivary cell 8-OHdG with respect to Ser/Cys and Cys/Cys genotypes of OGG1 in SCCHN cases, when compared to Ser/Ser and Ser/Cys genotypes of the control population. Our results demonstrate that Ser326Cys variant genotype is associated with an increased risk of SCCHN in north India. Ser326Cys variant genotype was found to accumulate more of 8-OHdG, which may serve as a biomarker for early diagnosis of SCCHN.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21986195     DOI: 10.1016/j.mrgentox.2011.09.015

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  8 in total

Review 1.  A systematic review and meta-analysis of the association between OGG1 Ser326Cys polymorphism and cancers.

Authors:  Ping-Ting Zhou; Bo Li; Jun Ji; Meng-Meng Wang; Chun-Fang Gao
Journal:  Med Oncol       Date:  2015-01-15       Impact factor: 3.064

2.  Reduced expression of DNA repair genes (XRCC1, XPD, and OGG1) in squamous cell carcinoma of head and neck in North India.

Authors:  Anil Kumar; Mohan Chand Pant; Hirdya Shanker Singh; Shashi Khandelwal
Journal:  Tumour Biol       Date:  2011-11-15

3.  Association between polymorphisms in genes related to DNA base-excision repair with risk and prognosis of oropharyngeal squamous cell carcinoma.

Authors:  Ericka Francislaine Dias Costa; Erika Stocco Santos; Vitor Teixeira Liutti; Frederico Leal; Vivian Castro Antunes Santos; José Augusto Rinck-Junior; Fernanda Viviane Mariano; Cláudia Malheiros Coutinho-Camillo; Albina Altemani; Carmen Silvia Passos Lima; Gustavo Jacob Lourenço
Journal:  J Cancer Res Clin Oncol       Date:  2016-07-02       Impact factor: 4.553

4.  OGG1 Mutations and Risk of Female Breast Cancer: Meta-Analysis and Experimental Data.

Authors:  Kashif Ali; Ishrat Mahjabeen; Maimoona Sabir; Humera Mehmood; Mahmood Akhtar Kayani
Journal:  Dis Markers       Date:  2015-05-19       Impact factor: 3.434

5.  Association of polymorphisms hOGGI rs1052133 and hMUTYH rs3219472 with risk of nasopharyngeal carcinoma in a Chinese population.

Authors:  Ying Xie; Yuan Wu; Xunzhao Zhou; Mengwei Yao; Sisi Ning; Zhengbo Wei
Journal:  Onco Targets Ther       Date:  2016-02-12       Impact factor: 4.147

6.  Association between the OGG1 Ser326Cys Polymorphism and Cancer Risk: Evidence from 152 Case-Control Studies.

Authors:  Hua Zou; Qing Li; Wei Xia; Yong Liu; Xi Wei; Dong Wang
Journal:  J Cancer       Date:  2016-06-23       Impact factor: 4.207

7.  DNA repair genes polymorphisms and genetic susceptibility to Philadelphia-negative myeloproliferative neoplasms in a Portuguese population: The role of base excision repair genes polymorphisms.

Authors:  Ana P Azevedo; Susana N Silva; João P De Lima; Alice Reichert; Fernando Lima; Esmeraldina Júnior; José Rueff
Journal:  Oncol Lett       Date:  2017-04-21       Impact factor: 2.967

Review 8.  Association between OGG1 Ser326Cys polymorphism and risk of upper aero-digestive tract and gastrointestinal cancers: a meta-analysis.

Authors:  Sambuddha Das; Sayantan Nath; Aditi Bhowmik; Sankar Kumar Ghosh; Yashmin Choudhury
Journal:  Springerplus       Date:  2016-02-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.